View in EDS

Evaluation of antiproliferative effect of doxorubicin loaded zinc selenium quantum dots to MCF-7 cell lines by linagliptin functionalized lignin nanoparticles.

Saved in:
Bibliographic Details
Title: Evaluation of antiproliferative effect of doxorubicin loaded zinc selenium quantum dots to MCF-7 cell lines by linagliptin functionalized lignin nanoparticles.
Authors: Liaqat, Sana1 (AUTHOR), Fatima, Batool1 (AUTHOR) batoolfatima@bzu.edu.pk, Hussain, Dilshad2 (AUTHOR), Imran, Muhammad3 (AUTHOR), Batool, Rafia1 (AUTHOR), Majeed, Saadat4 (AUTHOR), Najam-ul-Haq, Muhammad1,4 (AUTHOR) najamulhaq@bzu.edu.pk
Source: European Polymer Journal. Mar2024, Vol. 208, pN.PAG-N.PAG. 1p.
Subjects: Quantum dots, Doxorubicin, Cell lines, Linagliptin, Zinc selenide, Selenium, Lignins
Abstract: [Display omitted] • Linagliptin-coated lignin nanomaterial is loaded with zinc selenide quantum dots. • Doxorubicin is loaded on the synthesized biocompatible drug carrier. • The maximum drug encapsulation efficiency is 78.908%. • The as-synthesized LLQD-Doxo shows antioxidant activity due to lignin polyphenolic compounds. In this research study, biocompatible linagliptin functionalized lignin (LL) nanomaterial is synthesized to deliver doxorubicin and zinc selenide quantum dots (ZnSe QDs). Afterward, doxorubicin and ZnSe QDs are loaded in LL to form LLQD-Doxo and analyzed its tumor cell proliferation. Drug carriers are characterized by SEM, FTIR, XRD, DSC, TGA, and zeta potential. In vitro studies are performed at different temperatures, pH, time, and concentration. According to the results, maximum drug encapsulation efficiency is 78.91 %, and rapid drug release is observed at 45 °C and pH 6.5. Linagliptin attached to lignin acts as an inhibitor of xanthine-based non-peptidomimetic DPP-4, an antiproliferative cancer agent. LLQD-Doxo is released from lignin by diffusion at pH 6.5, which is favorable for the tumor microenvironment (TME). LLQD-Doxo exhibits significant therapeutic, anti-inflammatory, antioxidant, cytotoxic, and increased antioxidant activity for MCF-7 cells. The best anti-inflammatory and lipoxygenase inhibitory activity is 48.05 ± 1.05 % and 76.93 ± 2.03 %, respectively. LLQD-Doxo shows antioxidant activity due to lignin polyphenolic compounds in DPPH assay and free radical scavenging activity with IC = 64 μg/mL. Cytotoxicity assay also shows promising results, i.e., 82.32 ± 3.68 % of viable cells after treatment with LLQD-Doxo. The results depict that this drug carrier is suitable for drug delivery at acidic pH and high temperature conditions in tumor cells compared to normal cells. [ABSTRACT FROM AUTHOR]
Copyright of European Polymer Journal is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:[Display omitted] • Linagliptin-coated lignin nanomaterial is loaded with zinc selenide quantum dots. • Doxorubicin is loaded on the synthesized biocompatible drug carrier. • The maximum drug encapsulation efficiency is 78.908%. • The as-synthesized LLQD-Doxo shows antioxidant activity due to lignin polyphenolic compounds. In this research study, biocompatible linagliptin functionalized lignin (LL) nanomaterial is synthesized to deliver doxorubicin and zinc selenide quantum dots (ZnSe QDs). Afterward, doxorubicin and ZnSe QDs are loaded in LL to form LLQD-Doxo and analyzed its tumor cell proliferation. Drug carriers are characterized by SEM, FTIR, XRD, DSC, TGA, and zeta potential. In vitro studies are performed at different temperatures, pH, time, and concentration. According to the results, maximum drug encapsulation efficiency is 78.91 %, and rapid drug release is observed at 45 °C and pH 6.5. Linagliptin attached to lignin acts as an inhibitor of xanthine-based non-peptidomimetic DPP-4, an antiproliferative cancer agent. LLQD-Doxo is released from lignin by diffusion at pH 6.5, which is favorable for the tumor microenvironment (TME). LLQD-Doxo exhibits significant therapeutic, anti-inflammatory, antioxidant, cytotoxic, and increased antioxidant activity for MCF-7 cells. The best anti-inflammatory and lipoxygenase inhibitory activity is 48.05 ± 1.05 % and 76.93 ± 2.03 %, respectively. LLQD-Doxo shows antioxidant activity due to lignin polyphenolic compounds in DPPH assay and free radical scavenging activity with IC = 64 μg/mL. Cytotoxicity assay also shows promising results, i.e., 82.32 ± 3.68 % of viable cells after treatment with LLQD-Doxo. The results depict that this drug carrier is suitable for drug delivery at acidic pH and high temperature conditions in tumor cells compared to normal cells. [ABSTRACT FROM AUTHOR]
ISSN:00143057
DOI:10.1016/j.eurpolymj.2024.112867